psilocybin, the active ingredient in magic mushrooms, has proven itself to be effective against depression and physiologically safe. there are over 100 therapeutic psychedelic experiments going through the FDA approval process since the breakthrough status designation.
“At Day 21, following the second dose, 53% and 44% of patients in the 12 mg and 16 mg groups, respectively, were classified as responders (achieving a 50% or greater reduction in MADRS scores). By Day 126 (four months after the initial dose), the percentage of responders increased to 75% in both dosing groups.”
You must log in or # to comment.